Janki Shah, MD
Cardiovascular Disease · Santa Monica, CANPI 1497826325
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $25,582 of the $25,854 with a category attached, or 98.9%. Amgen accounts for 98.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $25,582 and has fallen 99.4% since, to $142 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 9 payments — averaging $2872.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$26K
- Heartflow, Inc.$142
- Abbott$98
- Baxter Healthcare$33
What the payments were for
- Consulting fees$25,58299%
- Food & beverage$2391%
- Other$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $25,582 |
| Heartflow, Inc. | 1 | $142 |
| Abbott | 1 | $98 |
| Baxter Healthcare | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,854 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 257 | $325,332 |
| XareltoRivaroxaban | 213 | $268,342 |
| EliquisApixaban | 175 | $241,916 |
| Praluent PenAlirocumab | 67 | $68,685 |
| EntrestoSacubitril/Valsartan | 19 | $34,327 |
| FarxigaDapagliflozin Propanediol | 23 | $33,431 |
| JardianceEmpagliflozin | 25 | $27,913 |
| VascepaIcosapent Ethyl | 24 | $23,165 |
| Rosuvastatin Calcium | 835 | $16,212 |
| Ezetimibe | 291 | $12,298 |
| DiovanValsartan | 18 | $10,992 |
| Metoprolol Succinate | 565 | $10,278 |
| Atorvastatin Calcium | 718 | $8,394 |
| Amlodipine Besylate | 683 | $6,383 |
| Losartan Potassium | 438 | $5,600 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Santa Monica
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.